^
Association details:
| Biomarker: | TPBG expression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | YH38560 (CD47 inhibitor, 5T4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
467 YH38560, a novel bispecific fusion protein targeting 5T4 and CD47 in a tumor-selective manner for the treatment of solid cancers
Published date:
11/08/2022
Excerpt:
In vivo anti-tumor effects of YH38560 were evaluated in human 5T4/CD47 expressing MC38 tumor model using hSIRPα knock-in (KI) mice as monotherapy and in combination with anti-PD-1 or PD-L1 antibody (Ab)….YH38560 alone showed significant tumor growth inhibition superior to monospecific CD47 blockers and it exerted synergistic and durable anti-tumor effects when combined with either anti-PD-1 or PD-L1 Ab in MC38 syngeneic mouse model.
DOI:
10.1136/jitc-2022-SITC2022.0467
